Overview

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Status:
Completed

Trial end date:
2019-08-01

Target enrollment:

Participant gender:

Summary

The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)

Phase:

Phase 2

Details

Lead Sponsor:

Yale University

Treatments:

Exenatide